Abstract: The present invention relates to 5?-cap compounds, in particular the stabilization of RNA by such 5?-cap compounds, and provides compositions, such as pharmaceutical compositions, and cells comprising an RNA which is modified with such a 5?-cap compound, as well as methods for producing a peptide or protein of interest using the compositions or cells according to the present invention. Furthermore, the present invention provides the RNA, compositions, or cells for use in therapy, in particular for use in a method of treating a disease or disorder by protein replacement therapy, genome engineering, genetic reprogramming, and immunotherapy; a method for increasing the stability of RNA in cells; a method for increasing the expression of RNA in cells; and a method for providing an RNA with a 5?-cap structure.

Abstract: The present invention relates to nucleic acid molecules containing poly(dA:dT) regions which are stabilized in E.coli, methods of propagating such nucleic acid molecules in E.coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly(dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

Abstract: A method is for controlling a nuclear power plant comprising a pressurized water nuclear reactor. The method includes determining that an obtained waiting period and/or a remaining waiting period is greater than a first predetermined time allowing raising of a Xenon concentration to maximal value. The method further includes, responsive to the determination, moving one or more control rods out of the reactor core for compensating the reactivity loss due to an increase of the Xenon concentration, and moving the one or more control rods into the reactor core to a control rod setpoint for the start of power ramp up before the end of the obtained waiting period and/or remaining waiting period.

Abstract: A first analytical instrument is configured to be controlled according to one or more first operating parameters; and controlling the configured first analytical instrument based on an estimated ion current obtained by: selecting at least one signal from stored data comprising a plurality of signals and a respective one or more second operating parameters associated with each of the plurality of signals, wherein each signal of the plurality of signals is representative of an ion current obtained using the first analytical instrument configured according to the respective associated one or more second operating parameters or using a second analytical instrument configured according to the respective associated one or more second operating parameters, and wherein the at least one signal is selected based on the one or more first operating parameters; and using the at least one selected signal to estimate the ion current.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E.-coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

Abstract: The present disclosure provides technologies for performing in vitro transcription that can generate product RNA preparations with reduced levels of certain contaminants (e.g., aberrant products), and particularly of double-stranded RNA (dsRNA).

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: The present disclosure relates to the fields of packaging, transportation, and storage of temperature-sensitive materials, such as biological and/or pharmaceutical products. Various aspects of such packaging, transportation, and storage are provided herein for ultra-low temperature materials useful for the treatment and/or prevention of disease. The present disclosure also provides packaging materials, methods of transportation, and methods of storage for maintaining biological and/or pharmaceutical materials at ultra-low temperatures in order to maintain the integrity of the materials. The present disclosure further relates to the field of RNA to prevent or treat coronavirus infection.

Abstract: A process for preparing a porous carbon material. The process comprises the process steps: providing a carbon source; providing an amphiphilic species; contacting the carbon source and the amphiphilic species to obtain a precursor; and heating the precursor to obtain the porous carbon material; wherein the carbon source comprises a carbon source compound, wherein the carbon source compound comprises an aromatic ring having one or more attached OH groups and an ester link.

Abstract: A process for the preparation of a porous carbon material using an improved amphiphilic species. Also disclosed are a porous carbon material, devices comprising the porous carbon material and use of an amphiphilic compound for the preparation of a porous carbon material. The process for preparing a porous carbon material comprises the process steps: (a) providing a carbon source comprising a first carbon source compound; (b) providing an amphiphilic species comprising a first amphiphilic compound, the first amphiphilic compound comprising two or more adjacent ethylene oxide-based repeating units; (c) contacting the carbon source and the amphiphilic species to obtain a precursor; and (d) heating the precursor to obtain the porous carbon material.

Abstract: A process for the preparation of a porous carbon material using an improved amphiphilic species. Also disclosed are a porous carbon material, devices comprising the porous carbon material and use of an amphiphilic compound for the preparation of a porous carbon material. The process for preparing a porous carbon material comprises the process steps: (a) providing a carbon source comprising a first carbon source compound; (b) providing an amphiphilic species comprising a first amphiphilic compound, the first amphiphilic compound comprising two or more adjacent ethylene oxide-based repeating units; (c) contacting the carbon source and the amphiphilic species to obtain a precursor; and (d) heating the precursor to obtain the porous carbon material.

Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

Abstract: The present disclosure provides technologies for in vitro transcription reactions, particularly for production of pharmaceutical grade RNA, and in some embodiments for large scale production.

Abstract: A process for preparing a porous carbon material. The process comprises the process steps: providing a carbon source; providing an amphiphilic species; contacting the carbon source and the amphiphilic species to obtain a precursor; and heating the precursor to obtain the porous carbon material; wherein the carbon source comprises a carbon source compound, wherein the carbon source compound comprises an aromatic ring having one or more attached OH groups and an ester link.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: A method is for controlling a nuclear power plant comprising pressurized water nuclear reactor (3) having a reactor core producing power, a primary circuit (5) connecting the reactor core to a steam generator (9), one or more of control rods (16), which can be moved into the reactor core for controlling the power of the reactor core, an injecting device (22, 23, 24, 26, 28, 30) for injecting boric acid and/or deionized water into the primary circuit (5) for controlling the reactivity of the reactor core.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.